- Report
- February 2023
- 220 Pages
Global
From €7203EUR$7,500USD£6,202GBP
- Drug Pipelines
- January 2022
- 30 Pages
Global
From €480EUR$500USD£413GBP
- Report
- January 2019
- 35 Pages
Global
From €960EUR$1,000USD£827GBP
- Report
- January 2021
- 148 Pages
Global, China
From €3000EUR$3,346USD£2,673GBP
- Report
- April 2023
- 94 Pages
Global
From €3500EUR$3,904USD£3,119GBP
- Report
- May 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,191GBP
- Report
- May 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,191GBP
- Report
- May 2024
- 50 Pages
Global
From €2545EUR$2,650USD£2,191GBP
- Report
- November 2023
- 215 Pages
China
From €3842EUR$4,000USD£3,308GBP
- Report
- November 2023
- 109 Pages
China
From €1729EUR$1,800USD£1,488GBP
Candesartan is a drug used to treat hypertension and congestive heart failure. It is a type of angiotensin II receptor antagonist, which works by blocking the action of a hormone that causes blood vessels to narrow. This helps to reduce blood pressure and improve the heart's ability to pump blood. Candesartan is also used to reduce the risk of stroke in people with high blood pressure and left ventricular hypertrophy.
Candesartan is available in both generic and branded forms. It is marketed by several pharmaceutical companies, including Novartis, Teva Pharmaceuticals, Mylan, and Sandoz. It is also available in combination with other drugs, such as hydrochlorothiazide and amlodipine.
In the cardiovascular drugs market, Candesartan is a popular choice for treating hypertension and congestive heart failure. It is well-tolerated and has a low risk of side effects. It is also cost-effective, making it an attractive option for many patients.
Companies in the Candesartan market include Novartis, Teva Pharmaceuticals, Mylan, and Sandoz. Show Less Read more